Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecinsGARCIA-CARBONERO, Rocio; SUPKO, Jeffrey G.Clinical cancer research. 2002, Vol 8, Num 3, pp 641-661, issn 1078-0432Article

Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogsSUPKO, Jeffrey G; GARCIA-CARBONERO, Rocio; PUCHALSKI, Thomas A et al.Cancer chemotherapy and pharmacology. 2001, Vol 48, Num 3, pp 202-208, issn 0344-5704Article

Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancerMEYERHARDT, Jeffrey A; CLARK, Jeffrey W; RYAN, David P et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 5, pp 661-670, issn 0344-5704, 10 p.Article

Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumorsSUPKO, Jeffrey G; EDER, Joseph P; RYAN, David P et al.Clinical cancer research. 2003, Vol 9, Num 14, pp 5178-5186, issn 1078-0432, 9 p.Article

A phase II study of weekly Paclitaxel in elderly patients with advanced non-small cell lung cancerFIDIAS, Panos; SUPKO, Jeffrey G; SKARIN, Arthur et al.Clinical cancer research. 2001, Vol 7, Num 12, pp 3942-3949, issn 1078-0432Article

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2HOLKOVA, Beata; SUPKO, Jeffrey G; KMIECIAK, Maciej et al.Clinical cancer research (Print). 2013, Vol 19, Num 7, pp 1873-1883, issn 1078-0432, 11 p.Article

A woman with a mass in the pelvisKRASNER, Carolyn N; ROCHE, Maria; HOROWITZ, Neil S et al.The New England journal of medicine. 2006, Vol 354, Num 15, pp 1615-1625, issn 0028-4793, 11 p.Article

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcomaLAVERDIERE, Caroline; KOLB, E. Anders; GOORIN, Allen M et al.Cancer. 2003, Vol 98, Num 4, pp 832-840, issn 0008-543X, 9 p.Article

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated dailyEDER, Joseph P; SUPKO, Jeffrey G; CONNORS, Susan et al.Journal of clinical oncology. 2002, Vol 20, Num 18, pp 3772-3784, issn 0732-183X, SUPArticle

A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumorsPENSON, Richard T; SUPKO, Jeffrey G; SEIDEN, Michael V et al.Cancer. 2001, Vol 92, Num 5, pp 1156-1167, issn 0008-543XConference Paper

Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular leydig cells in the adult ratAKINGBEMI, Benson T; BRADEN, Tim D; KEMPPAINEN, Barbara W et al.Endocrinology (Philadelphia). 2007, Vol 148, Num 9, pp 4475-4488, issn 0013-7227, 14 p.Article

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumorsEDER, Joseph P; RYAN, David P; SUPKO, Jeffrey G et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 1, pp 107-116, issn 0344-5704, 10 p.Article

A phase I study of bortezomib plus irinotecan in patients with advanced solid tumorsRYAN, David P; O'NEIL, Bert H; EDER, Joseph P et al.Cancer. 2006, Vol 107, Num 11, pp 2688-2697, issn 0008-543X, 10 p.Article

Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox-2 inhibitionMERCHAN, Jaime R; JAYARAM, Deepa R; SUPKO, Jeffrey G et al.International journal of cancer. 2005, Vol 113, Num 3, pp 490-498, issn 0020-7136, 9 p.Article

A Phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumorsSEIDEN, Michael V; NG, Shu-Wing; SUPKO, Jeffrey G et al.Clinical cancer research. 2002, Vol 8, Num 3, pp 691-697, issn 1078-0432Article

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicityPUCHALSKI, Thomas A; RYAN, David P; GUZMAN, Cecilia et al.Cancer chemotherapy and pharmacology. 2002, Vol 50, Num 4, pp 309-319, issn 0344-5704, 11 p.Article

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous LeukemiaATTAR, Eyal C; DEANGELO, Daniel J; LEVINE, James et al.Clinical cancer research. 2008, Vol 14, Num 5, pp 1446-1454, issn 1078-0432, 9 p.Article

The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochlorideGROSSMAN, Stuart A; CARSON, Kathryn A; BATCHELOR, Tracy T et al.Clinical cancer research. 2006, Vol 12, Num 17, pp 5174-5181, issn 1078-0432, 8 p.Article

Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinomaAMREIN, Philip C; CLARK, John R; MCINTYRE, James F et al.Cancer. 2005, Vol 104, Num 7, pp 1418-1427, issn 0008-543X, 10 p.Article

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibLYNCH, Thomas J; BELL, Daphne W; LOUIS, David N et al.The New England journal of medicine. 2004, Vol 350, Num 21, pp 2129-2139, issn 0028-4793, 11 p.Article

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in Patients with advanced solid tumorsRYAN, David P; EDER, Joseph P; PUCHLASKI, Thomas et al.Clinical cancer research. 2004, Vol 10, Num 7, pp 2222-2230, issn 1078-0432, 9 p.Article

Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumorsCAMPOS, Susanna M; MATULONIS, Ursula A; SEIDEN, Michael V et al.Gynecologic oncology (Print). 2003, Vol 90, Num 3, pp 610-618, issn 0090-8258, 9 p.Article

A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusionSUPKO, Jeffrey G; LYNCH, Thomas J; CLARK, Jeffrey W et al.Cancer chemotherapy and pharmacology. 2000, Vol 46, Num 4, pp 319-328, issn 0344-5704Article